Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ENO1 antisense RNA 1 (ENO1-AS1)
- Target
- ENO1-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense RNA
01
Overview
ENO1 antisense RNA 1 (ENO1-AS1) is a long noncoding RNA transcribed antisense to the ENO1 gene, which encodes alpha-enolase, a glycolytic enzyme. ENO1-AS1 is thought to function in the regulation of ENO1 expression at the transcriptional or post-transcriptional level through antisense mechanisms, including potential roles in chromatin modification, mRNA stability, or translational control. While dysregulation of related lncRNAs and antisense RNAs has been implicated in cancer and other diseases, the detailed biological and pathological functions of ENO1-AS1 remain under active investigation. No drugs currently target ENO1-AS1 directly, but its involvement in gene regulatory networks makes it a locus of interest for disease association studies and possible future RNA-targeted therapies.
- Other names
- ENO1 antisense RNA 1 (non-protein coding)ENO1-AS1lncRNA ENO1-AS1
02
Mechanism of action
Not established for drugs; mechanisms of ENO1-AS1 involve antisense RNA regulation—either by forming RNA-RNA duplexes to regulate ENO1 mRNA or influencing chromatin state/transcription at the ENO1 locus
03
Biological functions
Regulation of gene expression (by antisense RNA mechanisms)Post-transcriptional modulation of ENO1 mRNA or nearby gene targetsPotential involvement in regulation of cell proliferation or indirect effects on cellular metabolism (by influencing ENO1 expression)
04
Disease associations
Cancer (emerging studies suggest dysregulation of ENO1-AS1 may contribute to oncogenic processes, primarily via modulation of ENO1 or related pathways; direct evidence is still limited, and roles are under investigation)Other (Depending on future research, as most antisense lncRNAs are being studied for diverse regulatory roles)
05
Safety considerations
None established in a therapeutic context, as ENO1-AS1 is not targeted by drugs. If future RNA therapeutics are developed to modulate ENO1-AS1, concerns may include *off-target gene regulation* common to lncRNA-targeted therapeutics
06
Biomarkers
ENO1-AS1 may have *potential* as a biomarker in cancer research or diagnostics due to correlations with cancer-related pathways, but it is not currently in routine clinical use
Beyond the preview
Go deeper on ENO1 antisense RNA 1 (ENO1-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ENO1 antisense RNA 1 (ENO1-AS1).